tofacitinib
AssetAlso called CP-690,550, tofacitinib, CGB-500, Tofacitinib Citrate
Janus kinase (JAK) inhibitor that suppresses inflammatory cytokine signaling
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- JAK2
- 16
- Indications
- 144
- Trials
- 3
- Developers
Trial NCT04624230 is still running. Trial NCT04624230 updated in its registry on Aug 3, 2026. clinicaltrials.gov
Indications
16Rheumatoid arthritis
Phase 3, Completed, NCT02092467, clinicaltrials.gov, Oct 31, 2026
Ankylosing spondylitis
Phase 3, Completed, NCT03502616, clinicaltrials.gov, Oct 17, 2026
Arthritis juvenile idiopathic
Phase 3, Completed, NCT03000439, clinicaltrials.gov, Oct 17, 2026
13 more
In the full profile
- Target and mechanism4
- Owner and partners3
- Trials144
- Evidence for its targets5
- Competitors12
- Aging relevance2
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.